Pharma Journalist 8015 posts 0 comments

Novartis today announced that oral Fabhalta (iptacopan) has received U.S. Food and Drug Administration (FDA) approval for the treatment of adults with C3 glomerulopathy (C3G), to reduce…
Read More...

Altesa BioSciences, Inc., a clinical-stage pharmaceutical company dedicated to developing new treatments for viral infections in vulnerable populations, announced that the U.S. Food and…
Read More...

Oxford BioTherapeutics (OBT), a clinical stage oncology company with a pipeline of immuno-oncology (IO) and Antibody Drug Conjugate (ADC)-based therapies, announced a multi-year…
Read More...

OPKO Health, Inc. and Entera Bio Ltd., a leader in the development of oral peptides and proteins replacement therapies, entered into a collaboration and license agreement to advance…
Read More...

Salipro Biotech AB, a Swedish biotech company specialising in the stabilisation of challenging drug targets, announced a research and license agreement with Boehringer Ingelheim to…
Read More...

AstraZeneca and Alteogen Inc. have entered into an exclusive license agreement for ALT-B4, a novel hyaluronidase utilising Hybrozyme platform technology. Under the terms of the…
Read More...

AstraZeneca has entered into a definitive agreement to acquire EsoBiotec, a biotechnology company pioneering in vivo cell therapies that has demonstrated promising early clinical…
Read More...

Bristol Myers Squibb announced that the European Commission (EC) has granted approval to Breyanzi (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric antigen receptor (CAR) T…
Read More...

Latigo Biotherapeutics ("Latigo"), a clinical-stage biotechnology company developing best-in-class non-opioid pain treatments that target pain at its source, announced it has closed…
Read More...

Azurity Pharmaceuticals announced the successful completion of its acquisition of Covis Group S.à r.l. (“Covis”) from existing investors. With this acquisition, Covis is now a…
Read More...